In HCC, sorafenib therapy induces tumoural PD-L1 overexpression [130], and pre-clinical evidence in mouse models suggests this to correlate with T-reg accumulation and M2-macrophage polarisation through hypoxia, drawing a translationally appealing rationale for combination therapy [131]. The gene discussed is CD274; the disease is hepatocellular carcinoma.